close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

7.470 +0.330 (+4.62%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
From Evolus
Via Business Wire
News headline image
Telix Appoints David Gill as Chair
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
From Evolus
Via Business Wire
News headline image
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
From Evolus
Via Business Wire
News headline image
Evolus to Report Second Quarter Financial Results on August 5, 2026
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
From Evolus
Via Business Wire
News headline image
Evolus to Participate in The Jefferies Global Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
From Evolus
Via Business Wire
News headline image
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
From Evolus
Via Business Wire
News headline image
Evolus to Report First Quarter Financial Results on May 4, 2026
From Evolus
Via Business Wire
News headline image
Telix Appoints David Gill as Non-Executive Director
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026
From Evolus
Via Business Wire
News headline image
Evolus to Participate in The Leerink Partners Global Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Reports Third Quarter 2025 Financial Results
From Evolus
Via Business Wire
News headline image
Evolus to Participate in 2025 Stifel Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus to Report Third Quarter Financial Results on November 5, 2025
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
From Evolus
Via Business Wire
News headline image
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
From Evolus
Via Business Wire
News headline image
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Evolus
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.